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A B S T R A C T
Erythropoietin is a glycoproteic hormone that regulates hematopoiesis by acting on its speciﬁc receptor (EpoR).
The expression of EpoR in the central nervous system (CNS) suggests a role for this hormone in the brain.
Recently, we developed a new Epo variant without hematopoietic activity called EpoL, which showed marked
neuroprotective eﬀects against oxidative stress in brain ischemia related models. In this study, we have eval-
uated the neuroprotective eﬀects of EpoL against oxidative stress induced by chronic treatment with Aβ. Our
results show that EpoL was neuroprotective against Aβ-induced toxicity by a mechanism that implicates EpoR,
reduction in reactive oxygen species, and reduction in astrogliosis. Furthermore, EpoL treatment improved
calcium handling and SV2 levels. Interestingly, the neuroprotective eﬀect of EpoL against oxidative stress in-
duced by chronic Aβ treatment was achieved at a concentration 10 times lower than that of Epo. In conclusion,
EpoL, a new variant of Epo without hematopoietic activity, is of potential interest for the treatment of diseases
related to oxidative stress in the CNS such as Alzheimer disease.
1. Introduction
Erythropoietin (Epo) is a glycoprotein hormone belonging to the
superfamily of type I cytokines and is mainly responsible for the pro-
liferation, diﬀerentiation and maturation of erythroid cells, in both
embryonic and adult stages [1]. This hormone is a glycoprotein char-
acterized by having a glycosylation pattern conformed by 4 glycosy-
lated chains, 3 of them being N-glycosylations and one an O-glycosy-
lation [2], responsible for 40% of its molecular weight. Glycosylation
distribution gives a great heterogeneity to the mature protein, while the
absence of glycosylation reduces the stability of intermediate species
and causes changes in the binding kinetics of the erythropoietin re-
ceptor (EpoR) [3]. Additionally, the oligosaccharide chains attached to
Epo increase its molecular size and thereby prevent glomerular ﬁltra-
tion, while the presence of terminal neuraminic acids prevent the
hormone uptake by hepatic transporters, increasing their plasma half-
life [1,4–6]. Epo eﬀects produced by Epo/EpoR interaction activates
signaling cascades that act on the control of apoptosis.
The expression of EpoR has also been observed in non-erythroid
tissues explaining the pleiotropic eﬀects described for Epo. This re-
ceptor is expressed in the central nervous system (CNS) as a hetero-
dimer, which suggests a speciﬁc role of Epo in this tissue [6–8]. The
involvement of EpoR is critical for neuroprotection in vitro. For ex-
ample, in Alzheimer's Disease (AD), the accumulation of beta amyloid
peptide (Aβ1-42) is directly related to cellular apoptosis and DNA frag-
mentation [9]. Those processes have been stopped with Epo pre-treat-
ment for 1 h (h) [10]. These results correlate with an increase in cog-
nitive function, as evaluated by the Morris water maze test [11].
Additionally, Epo treatment has been associated with stimulation of
neuronal proliferation in the dentate gyrus of the hippocampus in an
AD animal model [12,13]. These data correlate with results that show
an increase in EpoR expression in brain lysates from Alzheimer's pa-
tients as compared to brain lysates of healthy patients [14].
The Aβ peptide in AD is responsible for the loss of ionic homeostasis
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due to its ability to perforate the cell membrane forming a pore that
allows the massive entrance of cations, especially calcium, inducing
apoptosis and an imbalance of intracellular ATP [15,16]. There are
several molecules that prevent the activation of the apoptotic pathway
in cellular models pretreated with amyloid beta peptide, including er-
ythropoietin. Activation of EpoR initiates Bcl2 gene transcription,
which blocks apoptosis and prevents cell death [17–19]. Consequently,
Epo-induced neuroprotection mediated by EpoR activation causes an
inhibition of apoptotic proteins and blocks the activation of caspases in
AD models [11,20,21]. The blockade in caspase activity is directly re-
lated with other pathways activated by EpoR, e.g. the activation of Bcl-
xL inducing a decrease in reactive oxygen species (ROS) [17,22,23].
The relationship between these two eﬀects, and the activation of EpoR
has been demonstrated through the silencing of EpoR in astroglia using
small interfering RNA (siRNA) techniques [24].
Current evidence suggests that Epo treatments can reduce the da-
mage induced by diﬀerent stresses such as inﬂammatory or ischemic
brain processes, or neurodegenerative diseases [24–27]. Therefore, the
development of new Epo isoforms lacking hematopoietic eﬀects could
be considered as new potential targets which exert neuroprotection
without the risk of vascular damage. In previous work, we used a new
variant of Epo without hematopoietic activity (EpoL), but with neuro-
protective eﬀects on stress mediated by ROS [17]. Here, we evaluate if
EpoL can provide similar neuroprotective eﬀects against oxidative
stress mediated by the Aβ peptide as compared to the hematopoietic
Epo variant as control.
2. Materials and methods
Animal care and protocols were in accordance with the National
Institutes of Health recommendations and approved by the Ethics
Committee at the University of Concepcion and Autonomous University
of Madrid.
2.1. Epo expression and puriﬁcation
Recombinant human erythropoietin (Epo) was obtained from the
genetically transformed Chinese ovarian hamster cell line (CHO; ATCC
CCL-61, USA). The supernatant culture was centrifuged at 390 g
(10min) and puriﬁed by Blue-Sepharose and a chelating aﬃnity
chromatography column. Epo samples were quantiﬁed by a commercial
human Epo ELISA kit (R&D, USA) and stored at −80 °C.
2.2. Goat mammary gland adenoviral mediated Epo expression
Three nulliparous Saanen goats (Capra hircus) of around 1.8 years
old were used during the ﬁrst month of natural lactation. The expres-
sion of recombinant human erythropoietin was carried out by the re-
combinant adenoviral infusion method described elsewhere [35]. Milk
collection started 48 h after adenoviral vector inoculation and lasted for
12 days.
2.3. EpoL puriﬁcation from milk
The recombinant human EpoL was puriﬁed from skimmed goat milk
corresponding to the milk from days 2–6 in the mammary glands in-
fused with the AdhEpo vector, as was previously described [35]. Milk
was diluted in 100mM EDTA containing 150mM NaCl, at pH 4.0 and
stirred at 4 °C. The insoluble fraction was removed by centrifugation
and the supernatant was precipitated with 30% ammonium sulfate for
1 h at 4 °C. The supernatant was dialyzed overnight at 4 °C using 20mM
Tris–HCl, 1% Tween 20 at pH 7.4 and loaded into a Blue-Sepharose and
chelating aﬃnity chromatography column. EpoL was quantiﬁed by a
commercial human Epo ELISA kit (R&D, USA) and stored at −80 °C.
2.4. Cell culture assays
2.4.1. PC-12 cell line
(ATCC CRL-1721, USA): Cells were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM) (Hyclone, USA) with 5% fetal bovine serum,
5% horse serum, 100 U/ml penicillin, 100 g/ml streptomycin, and
2mM L-glutamine and were incubated under standard conditions
(37 °C, 5% CO2).
2.4.2. Primary culture of hippocampal neurons
Hippocampal neurons were obtained from 18-day-old
Sprague–Dawley rat embryos. The primary hippocampal cultures were
maintained in a neuronal feeding medium consisting of 90% minimal
essential medium (HyClone, USA), 5% heat-inactivated horse serum
(HyClone, USA), 5% fetal bovine serum (Gibco, USA), and a mixture of
nutrient supplements. Cultures at 14–15 days in vitro (DIV) were treated
with Epo or EpoL at neuroprotective concentrations in co-incubation
with Aβ oligomers at 37 °C and 5% CO2.
2.4.3. Epo pre-treatment assay
PC-12 cells at 85% conﬂuence were pretreated with Epo or EpoL for
1 h and then stressed with Aβ40 peptide oligomers during 24 h using the
same medium with Epo or EpoL. Subsequently, the percentage of live
cells was quantiﬁed.
2.5. Soluble oligomers of Aβ
The human Aβ1–40 was dissolved in Dimethyl sulfoxide (DMSO,
Sigma- Aldrich) at a concentration of 80 μM and stored at −20 °C. The
soluble oligomer solution was freshly prepared from a stock external
solution and aggregated under standard conditions of 200 rpm at 37 °C
for 2 h [28]. The ﬁnal concentrations obtained for oligomers were
0.5 μM, 1 μM, and 5 μM. The oligomer species were previously de-
scribed and conﬁrmed [29,30]. Cells were treated for 24 h alone or co-
incubated with Epo or EpoL extracts at diﬀerent concentrations. The
Aβ25-35 peptide was obtained from Sigma (Madrid, Spain), dissolved in
phosphate buﬀer solution (PBS) and incubated with organotypic hip-
pocampus cultures at diﬀerent concentrations, according to the pro-
tocol previously described [31].
2.5.1. Cell viability assays
PC-12 cell cultures were seeded at a density of 90,000 cells/well and
used 24 h after plating. After exposing the cells to each experimental
condition, they were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (1mg/ml) for 30min,
and, thereafter, precipitated MTT was dissolved using isopropanol
cooled for 15min. The tetrazolium ring of MTT can be cleaved by active
dehydrogenases in order to produce a precipitated formazan com-
pound. Absorbance was measured in a multiplate reader (NovoStar,
LabTech BMG, Germany) at two wavelengths: 560 nm and 620 nm, and
the diﬀerence was quantiﬁed using NovoStar Software for the diﬀerent
experimental conditions.
2.5.2. Quantitative real time PCR
Total RNA of PC-12 cells treated was puriﬁed using TRIZOL (Sigma,
USA), and the reaction was performed with the commercial kit KAPA
SYBR FAST qPCR (KapaBiosystems, USA) and the equipment for
Stratagene MX3000P (ThermoFisher, USA) real-time PCR. The qPCR
was performed using RNA as a template, and the primers were ordered
from Integrated DNA Technologies (Coralville, USA): BcL-2 (Forward:
GATGACTGAGTA CCTGAACCG, Reverse: CAGAGACAGCCAGGAGAA
ATC) and β-actin (Forward: CACTTTCTACAATGAGCTGCG, Reverse:
CTGGATGGCTACGTACATGG). The comparative threshold cycle values
were normalized for the β-actin reference gene and the results were
expressed as CT relative quantiﬁcation by the 2-ΔΔCT method.
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2.6. Organotypic hippocampal cultures
Organotypic hippocampal cultures were obtained from brains of
8–10 day old Sprague Dawley rats. Hippocampal slices (300 μm thick)
were prepared and separated in ice-cold Hank's balanced salt solution
(HBSS) composed of: glucose 15mM, CaCl2 1.3 mM, KCl 5.36mM, NaCl
137.93mM, KH2PO4 0.44mM, Na2HPO4 0.34mM, MgCl2 0.49mM,
MgSO4 0.44mM, NaHCO3 4.1 mM, HEPES 25mM, 100 U/ml of peni-
cillin, and 0.100mg/ml of gentamicin. Four slices were placed on
Millicell 0.4 μm culture inserts (Millipore, Spain) within each well of a
six well culture plate with culture media. The culture media was
composed of 50% minimal essential medium (MEM), 25% Hank's ba-
lanced salt solution, and 25% heat-inactivated horse serum (Life
Technologies, Spain). After 4 days in culture, the slices were treated
with β-amiloyd25-35 (Sigma-Aldrich, Spain) for 4 days, with or without
Epo or EpoL at previously determined neuroprotective concentrations
(Castillo et al., 2018). Cultures were maintained at 37 °C and 5% CO2,
and the medium was changed twice a week.
2.6.1. Cell death measurement of organotypic cultures
At the end of each experiment, organotypic cultures were loaded
with 1 μg/ml propidium iodide (PI) and Hoechst 33342 (Hoechst) for
30min at 37 °C and 5% CO2. PI and Hoechst ﬂuorescence from the
cornu Ammonis 1 (CA1) region was measured using a Fluorescence
inverted NIKON eclipse T2000-U microscope. Wavelengths of excita-
tion and emission for PI and Hoechst were 530 or 350, and 580 or
460 nm, respectively. Fluorescence analysis was performed using Image
J version 5.0 software. The amount of cell death was determined by the
ratio between PI signal and Hoechst ﬂuorescence. Data were normal-
ized using basal values as 100%.
2.6.2. ROS measurement in organotypic cultures
The ﬂuorescence probe CM-H2DCFDA (2′, 7′-dichlorodihydro-
ﬂuorescein diacetate) was used to determine ROS. After the treatment,
cultures were loaded with 5 μM CM-H2DCFDA and 1 μg/ml of Hoechst
for 30min at 37 °C and 5% CO2. CM-H2DCFDA crosses the cell mem-
brane and is hydrolyzed by intracellular esterase to the non-ﬂuorescent
form, dichlorodihydroﬂuorescein. This reacts with ROS to form di-
chloroﬂuorescein, a green ﬂuorescent dye. Fluorescence was measured
on an inverted ﬂuorescence microscope (inverted NIKON eclipse
T2000-U microscope). Fluorescence analysis was performed using
Image J version 5.0 software. ROS increase production in the CA1 re-
gion was determined by the ratio between DCFDA and Hoechst ﬂuor-
escence. Data were normalized using basal values as 100%.
2.6.3. Immunoﬂuorescence of hippocampus organotypic cultures
After treatments, hippocampal cultures were detached from the
insert culture to evaluate diﬀerences in the expression of microglia
(using ionized calcium binding adaptor molecule-1 protein, Iba-1, as a
marker) and astrocytes (using glial ﬁbrillary acidic protein, GFAP, as a
marker). Slices were ﬁxed using paraformaldehyde (4%) for 1 h and the
sections were washed three times for 5min with PBS. The slices were
permeabilized using Triton (0.1%) solution for 10min and blocked with
normal goat serum and BSA for 1 h. The cultures were incubated with
anti-Iba-1 (Wako Chemicals, Rafer S.L) or with an anti-GFAP (Millipore,
Spain) antibody over-night at a dilution of 1:500. After washing with
PBS, sections were incubated with anti-rabbit IgG or anti-mouse IgG
secondary antibodies, respectively, for 2 h and 30min at a dilution of
1:800. Then, slices were washed for three times for 5min with PBS,
applying in the second wash 1 μg/ml Hoechst 33342. The montage was
made with Dako mounting medium (Agilent, USA). Images were taken
on a confocal microscope (TCS SPE; Leica, Wetzlar, Germany) and
analyzed using the software Image J and plugin Neuron, version 5.0.
2.6.4. Calcium transients
Calcium (Ca+2) transients were measured in cells loaded with
Fluo4-AM (Invitrogen), a non-ﬂuorescent acetoxymethyl ester calcium
indicator. Hippocampal neurons were cultured on coverslips coated
with poly-L-lysine (Sigma-Aldrich) and incubated with Fluo4-AM (5
μM) for 30min at 37 °C. Thereafter, the neurons were washed twice and
mounted on a perfusion chamber on a TE2000 microscope (Nikon).
Fluo4-AM was excited at 480 nm wavelength, and the emission was
recorded at 535 nm. Changes in cytosolic Ca+2 were registered with an
EM CCD camera (iXon ANDOR) and a Lambda 10B (Sutter Instruments)
interface. Regions of interest were simultaneously selected on neuronal
somata containing Fluo-4 ﬂuorescence in an optical ﬁeld having usually
more than 10 cells. The Ca+2 spikes were obtained as previously de-
termined [32]; brieﬂy, the spikes were analyzed individually from each
neuron with an Imaging Workbench 6.0 software (Indec System), and
the frequency for each experimental condition was obtained from the
number of Ca+2 increases in the cell body during the recording time
(200 s). The external solution used to incubate the dye and measure the
frequency of Ca2+ oscillations contained (in mM): 150 NaCl, 5.4 KCl,
2.0 CaCl2, 1.0 MgCl2, 10 glucose, and 10 HEPES (pH 7.4, 330 mOsmol).
2.6.5. Statistical analysis
Data in the graphics is expressed as mean ± SEM. Statistical ana-
lyses of the results were performed using one-way ANOVA with Tukey
test or Kruskal-Wallis and Dunns test, as appropriate. Statistical sig-
niﬁcance was considered as: *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 versus stressed cells (Aβ treatments); +p < 0.05, +
+p < 0.01 and +++p < 0.001, ++++p < 0.0001 versus
control group; #p < 0.05, ##p < 0.001, ###p < 0.001,
####p < 0.0001 versus treated cells (+Epo, +EpoL
or + EpoL + Anti-EpoR).
3. Results
3.1. EpoL has neuroprotective eﬀect against stress induced by chronic
treatment with Aβ40
The neuroprotective eﬀect was evaluated by the MTT assay in PC
12 cells co-incubated with soluble oligomers of Aβ40 (1 μM) for 24 h
and increasing concentrations of EpoL or Epo (10; 50; 100 ng/mL). Aβ
alone reduced cellular viability to 59.4% (± 2.57). Co-incubations
with EpoL or Epo achieved minimum neuroprotective eﬀects at 10 and
100 ng/mL, respectively; whereas the maximum eﬀect of EpoL was at
50 ng/mL with a 76.08% (± 6.72) of cellular viability, and the max-
imum eﬀect for Epo was at 100 ng/mL with a 66.27% (±6.12) of
neuroprotection (Fig. 1A). These concentrations were selected to eval-
uate the involvement of the EpoR in neuroprotective eﬀects. We then
co-incubated neuronal cultures with an antibody (Ab) to block the in-
teraction between hormone variants and the receptor (Fig. 1B). The
neuroprotective eﬀect of Epo and EpoL against Aβ was dependent on
the interaction with the EpoR. Furthermore, we evaluated the anti-
apoptotic pathways activated by Epo and EpoL co-incubation using
qRT-PCR. The results demonstrated that neurons treated with Aβ in the
presence of Epo or EpoL showed a signiﬁcant increase in the expression
of the antiapoptotic gene BcL-2, as measured by qPCR (Fig. 1C).
3.2. EpoL co-incubation prevents the decrease in spontaneous intracellular
calcium oscillations induced by Aβ40 treatment
To evaluate the eﬀect of hormone variants on spontaneous calcium
handling, primary hippocampal cultures were co-incubated with Epo or
EpoL at neuroprotective concentrations previously determined, and Aβ
oligomers for 24 h. The cells were then loaded with Fluo 4AM dye
(Fig. 2A). Quantiﬁcation of oscillation frequency, expressed as per-
centage of control (Fig. 2B), showed that Aβ treatment caused a sig-
niﬁcant decrease in this parameter to 33.96% (±4.45), whereas in
cells co-incubated with Aβ and EpoL, the oscillation frequency per-
centage was restored to control levels (115% ± 5.9). Co-incubation
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with Epo did not show total recovery of the response (72.42% ± 1.2)
as observed for EpoL (representative lines are shown in Fig. 2C).
Moreover, when cells were co-incubated with anti-EpoR plus EpoL
and Aβ in the way that is described in Fig. 3A, the recovery of the
intracellular calcium response previously described was lost. The
quantiﬁcation of the frequency calcium transients using anti-EpoR was
46.5% ± 14.08, similar to that observed with Aβ treatments
(33.96% ± 4.45) (Fig. 3B), suggesting a relevant role for EpoR on EpoL
eﬀects. Representative time course of one neuron for each condition are
shown in panel C of Fig. 3.
3.3. EpoL treatment preserves key elements of synaptic architecture against
Aβ40 synaptotoxicity
It has been widely observed that neurotoxicity is one of the most
common signals for synaptic failure, and these events are associated to
changes in protein levels of the synaptic machinery. For example,
changes in levels of presynaptic proteins such as synaptic vessel 2
proteins (SV2) aﬀect neurotransmitter release and could be correlated
with the decrease in spontaneous calcium transients which reﬂects a
post-synaptic response that could be a result of the toxicity induced by
Aβ40 [33]. To test this hypothesis, we used an immunocytochemistry
approach to measure the immunoreactivity of SV2 proteins (Fig. 4, left
panel, green color). A decrease in SV2 levels were observed when the
neurons were treated with Aβ (1 μM, 24h), and these results could help
to explain part of the changes in Ca2+ frequency, as previously de-
scribed [34]. Therefore, we decided to evaluate the eﬀect of EpoL co-
incubation on SV2 levels using immunoﬂuorescence to determine the
variations of this protein in neurons. Quantiﬁcation of SV2 on Map-2
reactive cells (Fig. 4, left panel, red color) was performed. We observed
a decrease in SV2 to 68.04% (±5.34) in Aβ treated neurons with re-
spect to control conditions. When neurons were co-incubated with EpoL
and Aβ, SV2 levels were similar to control values (99.83% ± 7.76),
suggesting a protective eﬀect (Fig. 4, right panel).
3.4. EpoL prevents ROS increase induced by Aβ25-35 chronic treatment in
hippocampal organotypic cultures
Organotypic hippocampal cultures, obtained as previously de-
scribed, were exposed for 4 days to Aβ25-35 (0.5 μM) and showed an
increase in local ROS as measured by changes in the ﬂuorescence of
DFCDA, about 148 ± 4.1% in the CA1 region, with respect to control
conditions (Fig. 5A, second frame). Using the same experimental ap-
proach, co-incubation with neuroprotective concentrations of Epo or
EpoL (100 ng/mL) demonstrated a signiﬁcant reduction in ROS induced
by Aβ; while Epo elicited values near control conditions
Fig. 1. EpoL induced a protective eﬀect against stress induced by chronic Aβ treatment. (A) Viability assay in PC12 cells treated with oligomers of Aβ40 (1uM)
for 24 h and Epo or EpoL at diﬀerent concentrations. The percentage of viability response was evaluated by MTT. (B) Viability assay using a speciﬁc antibody to block
interaction between EpoR and EpoL or EpoL. (C) Evaluation of the relative expression of the Bcl-2 gene using β-actin as a housekeeping gene after 24 h of treatment
with Aβ and co-treatment with Epo or EpoL, at the neuroprotective concentrations observed. Values are mean ± SEM, n = 3 using one-way ANOVA and Dunns test.
*:p < 0.05; **:p < 0.01 versus PC12 cells treated with Ab; ++++:p < 0.0001 versus control cells.
Fig. 2. EpoL treatment restored calcium homeostasis in neuronal cells exposed to Aβ. (A) Hippocampal neurons were treated for 24 h with oligomers of Aβ40
and co-incubated with Epo or EpoL at neuroprotective concentrations, as represented in the scheme on the top part of ﬁgure. (B) Quantiﬁcation of percentage
frequency of calcium transients using Fluo4AM loaded cells treated for 24 h with the diﬀerent treatments. (C) Representative images of calcium transients over a
200 s period in cells exposed to the diﬀerent indicated treatments. Values are mean ± SEM, n = 3 using one-way ANOVA and Dunns test. ***:p < 0.001;
****:p < 0.0001 versus neuronal cells treated with Aβ; ++++:p < 0.0001 versus control cells; ###:p < 0.001; ####:p < 0.0001 versus EpoL or Epo
treatment.
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(114 ± 11.5%), EpoL maintained ROS production about 78 ± 4.14%,
suggesting more eﬃcient antioxidant properties. (Fig. 5 B). This anti-
oxidant protection could represent a key event to avoid cell death in the
hippocampus and induce a delay in neuronal network degeneration in
relevant areas, such as CA1.
3.5. EpoL prevents cell death induced by Aβ25-35 chronic treatment in
hippocampal organotypic cultures
To corroborate the previous observation related with the anti-
oxidant properties of EpoL, we analyzed cell death in hippocampal
organotypic cultures treated for 4 days with Aβ25-35 (0.5 μM) oligomers
using PI dye as a cell death indicator (see materials and methods). Using
the same experimental conditions for Fig. 5, we observed that the
treatment with Aβ alone induced an increment in PI intensity about
176 ± 17.4%, representing close to 80% more death than control
conditions (Fig. 6A). On the other hand, co-incubation of the slices with
EpoL reduced PI ﬂuorescence to levels similar to control cultures
(98 ± 14.1%). Surprisingly, in this model, co-incubation with Epo did
not provide protection (191.9 ± 20.2%), showing very similar values
to the Aβ condition and higher than control (Fig. 6B).
Fig. 3. The intracellular calcium modulating eﬀects of EpoL in Aβ treated neurons is EpoR dependent. (A) Hippocampal neurons were treated for 24 h with
oligomers of Aβ40 and co-incubated with EpoL and a speciﬁc antibody at neuroprotective concentrations, as represented in the schematic. (B) Quantiﬁcation of
percentage frequency of calcium transients in Fluo4AM loaded cells treated for 24 h with Aβ or Aβ+EpoL or Aβ+ EpoL + Aβ, respectively. (C) Representative
images of calcium transients during 200 s, under the indicated treatments. Values are mean ± SEM, n = 3 using one-way ANOVA and Dunns test. ****:p < 0.0001
versus neuronal culture treated with Aβ; ++++:p < 0.0001 versus control cells; ####:p < 0.0001 versus EpoL or Epo treatment.
Fig. 4. Neuroprotective eﬀect of EpoL on synaptic markers induced by chronic treatments of Aβ. (A) Confocal images of neuronal cultures treated for 24 h with
oligomers of Aβ40 and co-incubated with EpoL at neuroprotective concentrations to analyze Map2 and SV2. (B) The number of SV2 punctas observed in the ﬁrst
20 μm of each neuron after 24 h of co-incubation is represented. Values are mean ± SEM, n = 3 using one-way ANOVA and Dunns test. ***:p < 0.001 versus
neuronal culture treated with Aβ; +++:p < 0.001 versus control cells.
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3.6. The neuroprotective eﬀect of EpoL in organotypic cultures is related to
EpoL-EpoR interaction
To corroborate that these important eﬀects observed in organotypic
tissues were related with the interaction of EpoL with the receptor
(EpoR), as was demonstrated in cell cultures, the same experimental
approaches used in Figs. 5 and 6 were replicated, using a speciﬁc anti-
EpoR antibody (Ab) with the aim of blocking the interaction between
EpoL and EpoR. As represented in Fig. 7, co-incubation with the anti
EpoR antibody prevented the neuroprotective eﬀects of EpoL in terms
of its capacity to reduce ROS production (Fig. 7A), avoid neuronal
death, and neuroprotection (Fig. 7B), showing no statistical diﬀerences
with the Aβ condition. These data suggest that the EpoR could be an
important part of the neuroprotective mechanism of EpoL.
3.7. EpoL prevents glial activation induced by Aβ treatment in hippocampal
organotypic cultures
It has been demonstrated in the CNS that an important factor to
induce ROS is glial activation. Hence, we decided to examine the
changes in astrogliosis levels to correlate with our previous observation
regarding the capacity of EpoL to reduce ROS in cells treated with Aβ25-
35. To evaluate this, we analyzed the morphological changes associated
to astrogliosis induced by chronic treatment with Aβ25-35 in hippo-
campal organotypic cultures [31]. Immunoﬂuorescence was assessed to
determine variations on glial ﬁbrillary acidic protein (GFAP) intensity
signal according to the protocol shown in Fig. 8A. Immunoﬂuorescence
quantiﬁcation of tissues treated with Aβ showed an increment of
60.2 ± 3% with respect to control conditions. However, co-incubation
Fig. 5. EpoL treatment decreased oxida-
tive stress in hippocampal organotypic
cultures. (A) Epiﬂuorescence images of
hippocampal organotypic cultures treated
for 4 days with Aβ25-35 (0.5 μM) and co-
incubated with EpoL or Epo at neuropro-
tective concentrations. (B) Images showing
the ﬂuorescence intensity of DCF-DA/
Hoechst signal in CA1 region. Values are
mean ± SEM, n = 5 using one-way
ANOVA and Tukey test. ****:p < 0.0001
versus neuronal culture treated with Aβ; +
+++:p < 0.001 versus control cells;
###:p < 0.001 versus Epo treatment.
Fig. 6. Neuroprotective eﬀect of EpoL in
hippocampal organotypic cultures
against stress induced by chronic treat-
ments of Aβ. (A) Epiﬂuorescence images of
hippocampal organotypic cultures treated
for 4 days with Aβ25-35 (0.5 μM) and co-
incubated with EpoL or Epo at neuropro-
tective concentrations. (B) Representative
ﬂuorescence images of PI/Hoechst signal of
the CA1 region. Values are mean ± SEM,
n = 5 using one-way ANOVA and Tukey
test. ****:p < 0.0001 versus neuronal
culture treated with Aβ; +++
+:p < 0.001 versus control cells;
###:p < 0.001 versus Epo treatment.
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with EpoL and Aβ demonstrated a reduction to 27.7 ± 2%. A similar
eﬀect was found for Epo that showed a 26.5 ± 2% increase with re-
spect to control (Fig. 8 B). These values were obtained from the analysis
of the images shown in Fig. 8C, and correlate with results found in
tissues under diﬀerent experimental conditions shown in Fig. 8D. Taken
together, these data suggest that the Anti-ROS eﬀects of EpoL could be
associated to the reduction in glial activation, and also to the intrinsic
eﬀects on neurons associated to one survival pathway through EpoR
activation.
4. Discussion
The method used to produce erythropoietin in this study resulted in
a new variant of Epo with a diﬀerent glycosylation pattern character-
ized by neutral, bi-antennary and a-sialylated structures, termed EpoL.
These characteristics demonstrated a marked reduction in hemato-
poietic activity as previously described [17,35]. In spite of this prop-
erty, EpoL interacted with EpoR in the same way as Epo and activated
the JAK/STAT pathway leading to overexpression of Bcl-2 family genes,
similarly to Epo [17,24]. In our previous work, we demonstrated an
improved eﬀect of EpoL to protect CNS cells treated with oxidative
agents in in vitro and ex vivo models, showing that EpoL was more
potent than Epo to provide neuroprotection [17]. In this study, by using
diﬀerent chronic Aβ models, we have been able to show a similar
neuroprotective proﬁle of EpoL when compared to Epo. It is notable to
point out that the concentrations required to achieve a similar
Fig. 7. The neuroprotective eﬀect of EpoL in
hippocampal organotypic cultures against Aβ
stress depended on EpoR interaction: (A)
Quantiﬁcation of ﬂuorescence signal intensity of
DCF-DA/Hoechst on the CA1 region of hippocampus
obtained by ﬂuorescence images of hippocampi or-
ganotypic cultures treated for 4 days with Aβ25-35
(0.5 μM) and co-incubated with EpoL or
EpoL + Anti-EpoR (Ab). (B) Quantiﬁcation of PI/
Hoechst signal of the CA1 region, as the same con-
ditions used in A. Values are mean ± SEM, n = 7
using One-way ANOVA and Tukey test.
***:p < 0.001, “ns” versus Aβ; ###:p < 0.001
versus ctrl.
Fig. 8. EpoL and Epo prevented astrogliosis induced by chronic treatment with Aβ. (A) Immunoﬂuorescence confocal images of organotypic hippocampal
cultures treated for 4 days with Aβ25-35 (0.5 μM) and co-incubated with EpoL or Epo at a neuroprotective concentration to analyze GFAP intensity signal. (B) Scheme
of protocol used. (C) Mean intensity of GFPA ﬂuorescence in the CA1 observed under each experimental condition using ImageJ software. Values are mean ± SEM,
n = 3 using one-way ANOVA and Dunns test. ***:p < 0.001 versus culture treated with Aβ25-35; ++++:p < 0.001 versus control cells.
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neuroprotective pattern for EpoL was 10 times lower than that of Epo.
Furthermore, the protective actions of EpoL were mediated by the re-
ceptor as demonstrated by the use of the anti-EpoR antibody. This re-
sult, together with our previous work performed in oxidative stress
brain ischemia-models [17], further supports the notion that the neu-
roprotection actions of EpoL are receptor mediated.
Considering that EpoL and NonHem-EpoR interaction (expressed in
CNS) is similar to the Epo/EpoR interaction, we decided to evaluate the
eﬀects of EpoL and EpoR activation on presynaptic (SV2 levels) and
postsynaptic (Ca2+ levels) parameters as indicators of neuronal net-
work functionality in primary hippocampal neurons [33,36]. We and
others have established that cell death is recorded as a sustained cal-
cium increase [37]. While calcium transients are an indicator of sy-
naptic activity, as reﬂected in the activity induced through neuro-
transmitter release, Ca+2 entry into the post-synaptic component
through ligand-activated and voltage dependent channels involves its
access [33,38,39]. Therefore, calcium transients are correlated tightly
with the health of the presynaptic component and together represents
indicators of synaptic communication and network activity. It has been
described that SV2 levels are altered in in vitro AD models [15], which
represents a good indicator for presynaptic dysfunction, while a di-
minished frequency in calcium transients induced by chronic Aβ
treatment has been correlated with neurotoxicity and neuronal death
[15,28]. Nevertheless, Epo or EpoL co-incubations prevented this al-
teration in Ca+2 handling. In addition, EpoL showed a neuroprotective
eﬀect represented by preservation of normal intracellular Ca2+ oscil-
lations, and its oscillation frequency was similar to control conditions.
Interestingly, higher concentrations of Epo, compared to EpoL, were
required to maintain an oscillation frequency similar to control, sug-
gesting a major eﬃciency of EpoL to activate the EpoR. Because the
anti-EpoR antibody abolished the eﬀects of EpoL, we believe that the
EpoR is relevant for the neuroprotective eﬀects of EpoL (Fig. 3). Fur-
thermore, this eﬀect could be associated to the neuroprotective me-
chanism of EpoL, since it would reduce calcium overloading due to
chronic exposure to Aβ.
The decreased frequency in calcium transients could be correlated
to a diminished SV2 signal in neuronal cells treated with Aβ oligomers
[30,40]. These eﬀects were probably related to variations in in-
tracellular ionic homeostasis and release of neurotransmitters. We ob-
served neuroprotective eﬀects of EpoL on SV2 levels in neurons co-
treated with Aβ (Fig. 4). These results suggest another common neu-
roprotective mechanism between Epo and EpoL, according to the de-
monstrated eﬀect of Epo on neurotoxicity induced by glutamate release
[8,41]. Correlated with this evidence, the hippocampal organotypic
cultures treated with Aβ showed decreased oxidative stress and cellular
death when EpoL was co-incubated (Figs. 5 and 6, respectively). Fur-
thermore, EpoL prevented the increase in basal ROS induced in this ex
vivo model because incubation with the non-hematopoietic variant
signiﬁcantly decreased the DCF-DA signal, with respect to control slices
without EpoL treatment. Moreover, cell death was decreased with EpoL
co-incubation, as measured by PI ﬂuorescence; and this protective ef-
fect could be related to the induction of the antiapoptotic protein Bcl-2
(Fig. 1). As previously described with neuroprotective compounds that
decrease ROS in organotypic cultures, Epo and EpoL could reduce
oxidative stress by the activation of antioxidant pathways such as Nrf2
[22,31,42,43].
On the other hand, the amino acid composition of erythropoietin is
the same as EpoL; it has a hydrophobic core which may alter the in-
teraction of Aβ oligomers with the cellular membrane blocking the pore
formation process, similar to other neuroprotective agents reported in
in vitro treatments [44].
Finally, another indicator of oxidative stress and inﬂammatory
process related to chronic Aβ exposure is astrogliosis, which is char-
acterized by an atypical increase in the number and morphology of
astrocytes due to nearby neuronal death [45]. Using the same previous
experimental conditions, we evaluated diﬀerent parameters of glial
activation as a sign of chronic inﬂammatory processes related to neu-
rodegenerative diseases and other diseases where there exists an in-
creased oxidative stress, such as cerebrovascular infarct [44,46–48].
Here, we analyzed astrogliosis signs through the measurement of GFAP,
which is altered with Aβ treatments. We found that EpoL was able to
reduce astrogliosis, similar to our previous results using Epo, in
agreement with Nrf2 and antiapoptotic pathways induced by neuro-
protector agents (Fig. 8) [49–51].
5. Conclusions
In conclusion, the EpoL variant induced several beneﬁcial eﬀects in
the CNS such as reducing redox imbalance, neuronal cell death, and
diminished other toxicity markers like chronic inﬂammation and sy-
naptic dysfunction. All these eﬀects were mediated by the interaction
with the EpoR and subsequent activation. Taken together, the post-
transductional modiﬁcations of the EpoL variant promoted a speciﬁc
interaction with the neuronal EpoR receptor, and represents a relevant
ﬁnding that could lead to the development of a new pharmacological
strategy associated to the ﬁrst biological drugs designed to modulate
neuronal EpoR in the ﬁght against the deleterious eﬀects of AD on the
neuronal network. Therefore, our ﬁnding can help open a new chemical
and biological space to develop anti-AD Drugs.
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